pneumothorax/tyrosine

El enlace se guarda en el portapapeles.

Elija el tipo de clasificación

Página 1 desde 21 resultados

Pneumothorax triggered by EGFR-tyrosine kinase inhibitors in three microwave ablation candidates: A review of the literature.

Solo los usuarios registrados pueden traducir artículos

Iniciar sesión Registrarse

Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are widely used in patients with EGFR-mutant lung cancer. Meanwhile, thermal ablation such as microwave ablation has been an option for selected patients. Herein, we describe three cases of pneumothorax that occurred in

Outcomes of research biopsies in clinical trials of EGFR mutation-positive non-small cell lung cancer patients pretreated with EGFR-tyrosine kinase inhibitors.

Solo los usuarios registrados pueden traducir artículos

Iniciar sesión Registrarse

OBJECTIVE Research biopsies (RBs) are crucial for developing novel molecular targeted agents. However, the safety and diagnostic yields of RBs have not been investigated in EGFR mutation-positive non-small cell lung cancer (NSCLC) patients pretreated with epidermal growth factor receptor (EGFR)

Secondary spontaneous pneumothorax in patients with sarcoma treated with Pazopanib, a case control study.

Solo los usuarios registrados pueden traducir artículos

Iniciar sesión Registrarse

BACKGROUND The tyrosine kinase inhibitor pazopanib is used for treatment of sarcoma. Recent studies have suggested that the use of pazopanib may lead to the development of pneumothorax, an unexpected adverse effect in patients with sarcoma metastatic to the chest. METHODS We conducted a

Pneumothorax during Pazopanib Treatment in Patients with Soft-Tissue Sarcoma: Two Case Reports and a Review of the Literature.

Solo los usuarios registrados pueden traducir artículos

Iniciar sesión Registrarse

Pazopanib, a multitargeting tyrosine kinase inhibitor, has single-agent activity in patients with advanced soft-tissue sarcoma. Herein, we describe 2 cases of pneumothorax that occurred during pazopanib treatment in patients with soft-tissue sarcoma. These 2 patients had multiple lung metastases.

A Case Report of Secondary Simultaneous Bilateral Pneumothorax Due to Pazopanib Treatment.

Solo los usuarios registrados pueden traducir artículos

Iniciar sesión Registrarse

Secondary spontaneous pneumothorax almost always develops secondary to an underlying lung disease. A pneumothorax secondary to a malignancy is very rare, and is observed most frequently in soft tissue sarcomas. Pazopanib, a tyrosine kinase inhibitor, is used in metastatic soft tissue sarcomas

Anorexia, Hypertension, Pneumothorax, and Hypothyroidism: Potential Signs of Improved Clinical Outcome Following Apatinib in Advanced Osteosarcoma.

Solo los usuarios registrados pueden traducir artículos

Iniciar sesión Registrarse

Apatinib, a specific tyrosine kinase inhibitor (TKI) that targets mainly vascular endothelial growth factor receptor-2 (VEGFR-2) as well as Ret, c-Kit and c-Src, has been assessed in patients with advanced osteosarcoma (phase II), the primary report of which has been published in PMID

Bilateral spontaneous pneumothoraces in anaplastic thyroid cancer.

Solo los usuarios registrados pueden traducir artículos

Iniciar sesión Registrarse

Spontaneous pneumothorax is rarely associated with cancer. We describe a 73 year old man who presented with recurrent tumor in the right neck, mediastinal lymphadenopathy and bilateral pulmonary nodules after thyroidectomy. He was treated with lenvatinib and presented with bilateral pneumothoraces.

Suspected accelerated disease progression after discontinuation of nintedanib in patients with idiopathic pulmonary fibrosis: Two case reports.

Solo los usuarios registrados pueden traducir artículos

Iniciar sesión Registrarse

BACKGROUND The efficacy of nintedanib, a multitarget receptor tyrosine kinase inhibitor, has been demonstrated in recent randomized controlled trials involving patients with idiopathic pulmonary fibrosis (IPF). However, accelerated disease progression after nintedanib discontinuation has never been

Atypical response to erlotinib in a patient with metastatic lung adenocarcinoma: a case report.

Solo los usuarios registrados pueden traducir artículos

Iniciar sesión Registrarse

BACKGROUND Tyrosine kinase inhibitors are widely prescribed in thoracic oncology and have excellent responses as a first-line treatment for locally advanced or metastatic lung cancer with epidermal growth factor receptor mutations. The side effects of tyrosine kinase inhibitors are mostly

[Interstitial lung disease].

Solo los usuarios registrados pueden traducir artículos

Iniciar sesión Registrarse

This concise article summarizes recent advances in the field of interstitial lung disease (ILD) with particular focus on clinically relevant findings. As a novel treatment option for idiopathic pulmonary fibrosis (IPF), pirfenidone has been granted marketing authorization in the European Union for

[A case of metastatic renal cell carcinoma associated with Birt-Hogg-Dubé syndrome treated with molecular-targeting agents].

Solo los usuarios registrados pueden traducir artículos

Iniciar sesión Registrarse

A 56-year-old man was referred to our clinic because of left lumbar pain and a left solitary renal tumor (9. 8 cm in diameter) and bilateral pulmonary metastases detected by computed tomographic scan. Pathologic diagnosis following open radical nephrectomy was papillary renal cell carcinoma, G2,

Pazopanib and soft-tissue sarcomas. Too toxic.

Solo los usuarios registrados pueden traducir artículos

Iniciar sesión Registrarse

Soft-tissue sarcomas are rare tumours of mesenchymal origin. Patients with metastatic disease have a median survival of about 10 months. Doxorubicin, an anthracycline, is often used to reduce tumour volume, but it does not prolong overall survival. Pazopanib, a multiple tyrosine kinase inhibitor

Apatinib for Advanced Osteosarcoma after Failure of Standard Multimodal Therapy: An Open Label Phase II Clinical Trial.

Solo los usuarios registrados pueden traducir artículos

Iniciar sesión Registrarse

Antiangiogenesis tyrosine kinase inhibitors (TKIs) have been shown to prolong progression-free survival (PFS) in advanced osteosarcoma. Methylsulfonic apatinib is a TKI that specifically inhibits vascular endothelial growth factor receptor-2. We aim to assess apatinib in patients with

Apatinib for advanced sarcoma: results from multiple institutions' off-label use in China.

Solo los usuarios registrados pueden traducir artículos

Iniciar sesión Registrarse

Anti-angiogenesis Tyrosine kinase inhibitors (TKIs) have been proved to show promising effects on prolonging progression-free survival (PFS) for advanced sarcoma after failure of standard multimodal Therapy. Methylsulfonic apatinib is one of those TKIs which specifically inhibits VEGFR-2. This paper

Feasibility of re-biopsy and EGFR mutation analysis in patients with non-small cell lung cancer.

Solo los usuarios registrados pueden traducir artículos

Iniciar sesión Registrarse

BACKGROUND In cases of EGFR-tyrosine kinase inhibitor (TKI) failure, re-biopsy may be useful to understand resistance mechanisms and guide further treatment decisions. However, performing re-biopsy is challenging because of several hurdles. We assessed the feasibility of re-biopsy in advanced

Únete a nuestra
página de facebook

Herbal & Natural Medicine

La base de datos de hierbas medicinales más completa respaldada por la ciencia

Funciona en 55 idiomas
Curas a base de hierbas respaldadas por la ciencia
Reconocimiento de hierbas por imagen
Mapa GPS interactivo: etiquete hierbas en la ubicación (próximamente)
Leer publicaciones científicas relacionadas con su búsqueda
Buscar hierbas medicinales por sus efectos.
Organice sus intereses y manténgase al día con las noticias de investigación, ensayos clínicos y patentes.

Escriba un síntoma o una enfermedad y lea acerca de las hierbas que podrían ayudar, escriba una hierba y vea las enfermedades y los síntomas contra los que se usa.
* Toda la información se basa en investigaciones científicas publicadas.